Yarrow Bioscience (YARW) EBT (2017 - 2026)

Yarrow Bioscience (YARW) has reported EBT for 10 consecutive years, with -$2.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 49.56% year-over-year to -$2.9 million; the trailing twelve-month figure through Jun 2026 stood at -$20.8 million (up 45.91% YoY), and the FY2025 full-year result was -$26.7 million, up 32.84% from the prior year.
• EBT rose to -$2.9 million in Q2 2026 per YARW's latest filing, from -$3.6 million in the prior quarter.
• Across five years, EBT topped out at -$2.9 million in Q2 2026 and bottomed at -$12.2 million in Q3 2024.
• Historically, EBT has averaged -$7.7 million across 5 years, with a median of -$8.0 million in 2022.
• The sharpest annual moves came in 2024 and 2026: EBT plunged 100.25% in 2024, then surged 58.33% in 2026.
• Over 5 years, EBT stood at -$7.7 million in 2022, then increased by 20.6% to -$6.2 million in 2023, then sank by 95.22% to -$12.0 million in 2024, then soared by 52.15% to -$5.7 million in 2025, then jumped by 49.56% to -$2.9 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$2.9 million, -$3.6 million, and -$5.7 million for Q2 2026, Q1 2026, and Q2 2025 respectively.